NGM313 is a humanized monoclonal antibody that we have engineered to selectively agonize or activate the beta-klotho (KLB)-FGFR1c receptor complex. KLB-FGFR1c is involved in the regulation of body weight, triglycerides and cholesterol, as well as insulin sensitivity and the uptake of glucose in various tissues. We believe NGM313, with its extended half-life and sustained pharmacology profile, could enable meaningful body weight loss, improve insulin sensitivity and may serve as a valuable complementary therapeutic to existing diabetes treatments that promote insulin production.

We are investigating NGM313, a potential once-monthly or less frequent injection, for the treatment of type 2 diabetes, obesity and potentially NASH. We initiated Phase 1 human clinical trials in overweight or obese insulin-resistant volunteers in 2016, and will explore the effect of NGM313 treatment on body weight, insulin sensitivity and lipid profile. Under our collaboration agreement, Merck will have a one-time right to exercise an option to license NGM313 following human proof of concept.